Extracts of bacteria of the genus sphingomonas

Abstract

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to extracts of bacteria of the genus Sphingomonas, compositions comprising at least one bacterium of the genus Sphingomonas or said extracts, their uses, and their implementation in cosmetic methods. [Background technology]

[0002] Activation of the kallikrein / kinin system (KKS) results in the conversion of inactive proenzymes, factor XII and prekallikrein, into their active forms, i.e., activated factor XII (FXIIa) and kallikrein (KK). Kallikrein cleaves high-molecular-weight kininogen (HK), releasing bradykinin (BK). Bradykinin and its active metabolite, desArg9BK, bind to receptors B2 (RB2) and B1 (RB1), respectively. The interaction of the ligands BK and desArg9BK with their receptors RB2 and RB1 results in vasodilation, increasing vascular permeability, allowing water to exit the blood vessels and enter the tissues, potentially resulting in cell extravasation.

[0003] Therefore, bradykinin is involved in vasodilation and increases vascular permeability.The use of bradykinin antagonists is an effective alternative for all cosmetic disorders using the system described here above.

[0004] The present inventors have surprisingly demonstrated that extracts of bacteria of the genus Sphingomonas may be used as inhibitors of the kallikrein-kinin system, thereby reducing the occurrence of redness. Furthermore, the present inventors have shown that a composition containing an extract of Sphingomonas xenophaga can significantly reduce the occurrence of redness in a capsaicin-irritated skin model.

[0005] Skin redness is a skin disorder that occurs primarily on the face and can have a variety of causes. It can be short-lived (hot flashes) or permanent. Skin redness is characterized by vasodilation of capillaries.

[0006] This redness can be caused by a wide variety of factors, for example (i) external stimuli such as those caused by consumption of food or hot or alcoholic beverages, by sudden temperature changes, by heat or cold, by low relative humidity, by exposure of the skin to strong winds or drafts (fans, air conditioners), and by the application of certain surfactants, or (ii) redness associated with skin disorders, for example, rosacea, erythroderma, atopic dermatitis, seborrheic dermatitis, and (iii) redness following allergic skin reactions.

[0007] These red spots are often unattractive and often unpleasant, causing substantial psychological discomfort.

[0008] Skin irritated by capsaicin is used in particular as a model for sensitive skin.

[0009] Sensitive skin is generally defined by a particular reactivity of the skin.

[0010] This skin reactivity generally results in symptoms of discomfort in response to the subject's contact with a triggering factor, which may have various origins: the application of cold or heat to the sensitive skin surface, or the application of certain products, exposure to sudden temperature changes, etc. There are also related factors such as age and skin type.

[0011] The appearance of these discomfort symptoms (which appear within minutes of contact with the triggering element) is one of the essential characteristics of sensitive skin. These discomfort symptoms are mainly paresthesia, i.e., mildly unpleasant sensations felt in certain zones of the skin, such as tightness, tingling, itching, burning, discomfort, etc. Summary of the Invention [Means for solving the problem]

[0012] The present invention therefore relates to an extract of bacteria of the species Sphingomonas xenophagum.

[0013] Another object of the present invention is a composition comprising at least one bacterium of the species Sphingomonas xenophagum or an extract of bacteria of the species Sphingomonas xenophagum.The composition according to the invention is preferably a cosmetic product.

[0014] The present invention also relates to the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, as an inhibitor of bradykinin synthesis.

[0015] Another object of the present invention is a non-therapeutic cosmetic treatment method for skin redness, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas, or a composition comprising at least one bacterium of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas.

[0016] The present invention also relates to a non-therapeutic cosmetic treatment method for sensitive skin, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas, or a composition comprising at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas. [Brief explanation of the drawings]

[0017] [Figure 1] FIG. 1 shows the Vmax of plasma prekallikrein as a function of the concentration as a percentage of the extract of Sphingomonas. [Figure 2] 1 is a histogram showing the percentage activity of plasma prekallikrein as a function of the concentration of Sphingomonas extract used. [Figure 3] 1 is a histogram showing the change in clinical redness score over time. [Figure 4] 1 is a histogram showing the change in self-assessed redness score over time. DETAILED DESCRIPTION OF THE INVENTION

[0018] Extract of bacteria from the genus Sphingomonas The term "bacteria" refers to prokaryotic microorganisms, preferably Proteobacteria.

[0019] In the framework of the present invention, the term "bacterial extract" refers both to the set of compounds produced and / or secreted by bacteria and therefore present in the culture medium of a bacterial culture, and / or to the set of compounds contained in bacteria and therefore present in the bacterial pellet of a bacterial culture after centrifugation, e.g., the intracellular medium and / or components of the wall and / or cell membrane.

[0020] The extracts according to the invention may be prepared by any conventional method well known to those skilled in the art, which typically include the steps of fermentation, isolation, separation and purification.

[0021] Typically, Sphingomonas bacteria are cultured in a suitable medium and grown to a desired density. Preferably, the bacteria themselves are concentrated by any known method, such as centrifugation. The concentrated bacteria can then be used directly as a raw preparation or can undergo additional processing steps well known to those skilled in the art, such as lyophilization, dehydration, filtration, purification, freezing followed by optional thawing, sterilization, column chromatography, comminution, etc.

[0022] Preferably, the bacterial extract is a bacterial lysate, in particular comprising compounds contained in bacteria and therefore present in the bacterial pellet of the bacterial culture medium after centrifugation. Preferably, the bacterial extract is a bacterial lysate, comprising intracellular medium and / or components of the wall and / or cell membrane.

[0023] Lysate generally refers to the material obtained at the end of the destruction or decomposition of biological cells by a phenomenon called cell lysis, thus resulting in the release of intracellular biological components naturally contained in the cells of the microorganism under consideration.

[0024] In the present terminology, the term lysate is used to refer, on the contrary, to all of the lysate obtained by lysis of the microorganism under consideration, or to only a fraction of the microorganism under consideration.

[0025] The lysates performed are therefore in the form of whole or partial intracellular biological components, as well as components of the cell wall and membrane.

[0026] This cell lysis can be carried out using different techniques, such as by osmotic shock, heat shock, for example by freezing, optionally followed by lysis, sonication, or by subjecting to mechanical stress, for example of the centrifugation type.

[0027] Preferably, the lysate carried out in the framework of the present invention is subjected to the following steps: i) a step of centrifugation; ii) recovering the pellets; iii) freezing the pellets; iv) thawing the pellet; v) optionally sterilizing by autoclaving, in particular at 121°C The compound is obtained by a method comprising:

[0028] In certain embodiments of the present invention, the bacterial extract comprises inactivated bacteria.

[0029] Here, "inactivated" has the meaning commonly used by those skilled in the art, i.e., the inhibition of bacterial activity under the influence of various causes (thermal, chemical, mechanical, enzymatic). In particular, bacteria are inactivated by heat, more particularly by autoclaving.

[0030] The extract preferably has bradykinin inhibitory activity.

[0031] The bacterium of the extract according to the present invention is Sphingomonas xenophagum. In a preferred embodiment, the bacterium is Sphingomonas xenophagum, registered under the number CNCM I-5455 by L'Oreal (101 Avenue Gustave Eiffel, 37390 Notre Dame d'Oe) on November 21, 2019, in accordance with the Budapest Treaty, by the Collection Nationale de Culture de Microorganismes (CNCM, Paris, France).

[0032] Preferably, the extract is contained in a cosmetic composition in a cosmetically acceptable medium.

[0033] composition The present invention also relates to a composition, in particular a cosmetic composition, comprising at least one bacterium of the species Sphingomonas xenophagum or an extract as defined herein above.

[0034] Preferably, the cosmetic compositions according to the invention are intended to be administered topically.

[0035] Here, the term "cosmetic composition" has the meaning customarily used by those skilled in the art, and in particular refers to substances or preparations intended to be placed in contact with various surfaces of the human body, in particular the epidermis, hair system, nails, lips and external genitalia, as well as the mucous membranes of the oral cavity, exclusively or mainly for the purposes of cleansing, decorating, perfuming, modifying the aspect, protecting, keeping in good condition, or correcting body odor.

[0036] "Bacteria of the species Sphingomonas xenophagum" means bacteria in live, semi-active, inactivated or dead form.

[0037] The term "bacterial extract" is as defined in the paragraph Extract of bacteria of the genus Sphingomonas.

[0038] The amount of bacteria or bacterial extract in the composition according to the invention varies depending on the type of composition considered. Preferably, the amount of microorganism or extract is comprised between 0.0001% and 30% by dry weight relative to the total weight of the composition, between 0.001% and 15% by dry weight relative to the total weight of the composition, between 0.01% and 10% by dry weight relative to the total weight of the composition, preferably between 0.01% and 5% by dry weight relative to the total weight of the composition, or between 0.01% and 3% by dry weight relative to the total weight of the composition.

[0039] When the bacteria are present in the composition in a live form, the amount of live bacteria is 10 3 ~10 15 cfu / g, especially 10 5 ~10 15 cfu / g, more specifically 10 7 ~10 12 May vary in cfu / g of bacteria.

[0040] Preferably, the composition comprises a cosmetically acceptable medium.

[0041] Here, the term "cosmetically acceptable medium" refers to a non-toxic support that can be applied to keratinous materials such as the skin and mucous membranes. A cosmetically acceptable medium is therefore compatible with the skin, integument, and / or mucous membranes and does not induce any unpleasant sensations, or more generally, any disturbances, that could cause the user to discontinue or stop applying the cosmetic composition.

[0042] More particularly, the cosmetically acceptable medium may comprise water and / or one or more water-miscible organic solvents, which may be selected from linear or branched C1 to C6 monoalcohols, such as ethanol, isopropanol, tertio-butanol; polyols, such as glycerol, propylene glycol, hexylene glycol (o 2-methyl-2,4-pentanediol) and polyethylene glycol; polyol ethers, such as dipropylene glycol monomethyl ether; and mixtures thereof.

[0043] Preferably, the composition according to the present invention has a water content in the range of 20% to 95% by weight, more preferably 30% to 70% by weight, relative to the total weight of the composition.

[0044] Advantageously, the composition comprises one or more water-miscible organic solvents in a content ranging from 0.5% to 25% by weight, preferably from 5% to 20% by weight, more preferably from 10% to 15% by weight, relative to the total weight of the composition.

[0045] As is well known to those skilled in the art, the compositions for topical application may also contain additives common in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents different from the extract according to the invention, preservatives, antioxidants, fragrances, odor absorbers, colorants and mixtures thereof.

[0046] Preferably, the composition comprises: at least one additive chosen from hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents different from the extract according to the invention, preservatives, antioxidants, fragrances, odor absorbers, colorants and mixtures thereof, and / or at least one emulsifier, and / or - At least one oil Further includes:

[0047] The amounts of these various additives are those conventionally used in certain areas, for example 0.01% to 20% of the total mass of the composition.

[0048] Of course, the person skilled in the art will select these additional ingredients and / or active agents, and / or their amounts, so that the advantageous properties of the extract according to the invention are not altered or not substantially altered by the intended addition.

[0049] In an embodiment, the Sphingomonas bacterium or extract of Sphingomonas bacterium is the only active agent in the composition.

[0050] In another embodiment, the composition of the present invention may further contain other active agents different from the bacteria or extract according to the present invention, which may have an effect on vasodilation, redness, sensitive skin or other paresthesia factors.

[0051] In a particular embodiment of the invention, the composition according to the invention further comprises at least one active agent chosen from acetyl dipeptide-1 cetyl ester, extract of the root of Salvia miltiorrhiza, thermal water, for example La Roche Posay water, and mixtures thereof.

[0052] The compositions according to the invention can be in the form of any dosage form conventionally used for topical application, in particular aqueous solutions, aqueous alcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) or multiple (triple: W / O / W or O / W / O) emulsions, aqueous gels or dispersions of an oily phase in an aqueous phase using spheres, which are potentially lipid vesicles of ionic and / or non-ionic type (liposomes, niosomes, oleosomes). These compositions are prepared using conventional methods.

[0053] Advantageously, the composition according to the invention has the form of a gel or emulsion, a powder or a paste.Furthermore, the composition according to the invention can be somewhat fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam gel, a peel, a mask, a care, a tonic or a foam.Optionally, it can be applied to the skin in the form of an aerosol.It can also have a solid form, for example, in the form of a stick.

[0054] The composition according to the invention may comprise an oily phase.

[0055] Suitable oils for use in the compositions according to the invention include, for example: hydrocarbon oils, synthetic esters and ethers, in particular esters and ethers of fatty acids, such as oils of formulae R'COOR2 and R'OR2, where R' represents the residue of a fatty acid containing from 8 to 29 carbon atoms and R2 represents an optionally branched hydrocarbon chain containing from 3 to 30 carbon atoms; - linear or branched hydrocarbons of mineral or synthetic origin; - aliphatic alcohols having 8 to 26 carbon atoms, - partial hydrocarbon and / or silicone fluoride oils, - silicone oil, - A mixture of these Examples include:

[0056] The term "hydrocarbon oil" in the list of oils cited above means any oil containing primarily carbon and hydrogen atoms.

[0057] The oily phase may contain other fatty bodies that may be present in the oily phase, such as fatty acids containing 8 to 30 carbon atoms, waxes, silicone resins and silicone elastomers. These fats may be selected in various ways by those skilled in the art to prepare a composition with the desired properties, for example in terms of consistency or texture.

[0058] According to a specific embodiment of the present invention, the composition according to the present invention is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oily phase of the emulsion can be in the range of 5 to 80% by weight, preferably 5 to 60% by weight, relative to the total weight of the composition. The emulsion generally contains at least one emulsifier, used alone or in a mixture, selected from amphoteric, anionic, cationic, or nonionic emulsifiers, and optionally a co-emulsifier. The emulsifier is appropriately selected depending on the emulsion (W / O or O / W) to be obtained. The emulsifier and co-emulsifier are generally present in the composition in a proportion ranging from 0.3% to 30% by weight, preferably from 0.5% to 20% by weight, relative to the total weight of the composition.

[0059] In the case of W / O emulsions, emulsifiers include, for example, dimethicone copolyol and alkyl dimethicone copolyol. As surfactants for W / O emulsions, crosslinked solid elastomeric organopolysiloxanes containing at least one oxyalkylene group can also be used.

[0060] In the case of an O / W emulsion, the emulsifier may be, for example, a nonionic emulsifier.

[0061] The composition according to the present invention may be applied directly to the skin, or alternatively, to an occlusive or non-occlusive cosmetic support intended for topical application to the skin. Non-limiting examples of cosmetic supports include patches, wet wipes, and masks on a support. After application to the skin, the composition may or may not be rinsed off.

[0062] In a preferred embodiment, the composition used in the framework of the present invention is intended for topical application. In a preferred embodiment, the composition used in the framework of the present invention is intended for application to the skin.

[0063] In the framework of the present invention, the term "skin" refers to any skin surface of the body, preferably the skin of the face or legs, more particularly the skin of the face.

[0064] use The present invention relates to the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, as an inhibitor of bradykinin.

[0065] The bacteria used according to the invention, or the extract of the bacteria used according to the invention, are of the genus Sphingomonas. In embodiments, the bacterium is selected from the group consisting of Sphingomonas abaci, Sphingomonas adhaesiva, Sphingomonas aerolata, Sphingomonas aquatilis, Sphingomonas asaccharolytica, Sphingomonas aurantiaca, Sphingomonas azotifigens, Sphingomonas dokdonensis, Sphingomonas echinoides, Sphingomonas faenii, Sphingomonas faeni, Sphingomonas fennica, Sphingomonas haloaromaticamans, Sphingomonas jaspsi, Sphingomonas koreensis, Sphingomonas mali, Sphingomonas melonis, Sphingomonas natatoria, Sphingomonas oligophenolica, Sphingomonas panni, Sphingomonas parapaucimobilis parapaucimobilis, Sphingomonas paucimobilis, Sphingomonas phyllosphaerae, Sphingomonas pituitosapituitosa, Sphingomonas pruni, Sphingomonas roseiflava, Sphingomonas sanguinis, Sphingomonas soli, Sphingomonas sp., Sphingomonas suberifaciens, Sphingomonas trueperi, Sphingomonas wittichii, Sphingomonas xenophagum, Sphingomonas yabuuchiae, and Sphingomonas yunnanensis. The bacterium is a species selected from Sphingomonas yunnanensis and Sphingomonas yanoikuyae. In an embodiment of the present invention, the bacterium is Sphingomonas xenophagum. In a preferred embodiment, the bacterium is Sphingomonas xenophagum, registered under the Budapest Treaty on November 21, 2019, by the Collection Nationale de Culture de Microorganismes (CNCM, Paris, France) under the number CNCM I-5455 by L'Oreal (101 Avenue Gustave Eiffel, 37390 Notre Dame d'Oe).

[0066] Preferably, the use according to the invention relates to the use of at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas, or preferably a cosmetic composition according to the invention.

[0067] Preferably, the use according to the invention is a topical use: preferably, the bacterium or bacterial extract, or a composition containing same, is applied to the skin, more preferably to the face, legs or body, more preferably to the face.

[0068] The term "bradykinin inhibitor" refers to a compound that has the effect of inhibiting or reducing the biological activity of bradykinin. In an embodiment, the extract of a bacterium of the genus Sphingomonas of the present invention inhibits a reaction upstream of bradykinin activation, for example, by inhibiting or reducing activation of the kallikrein / kinin system (KKS) or by inhibiting or reducing activation of prekallikrein. Preferably, the extract of a bacterium of the genus Sphingomonas is used as an inhibitor of prekallikrein activation.

[0069] This inhibition inhibits vasodilation and increased vascular permeability.

[0070] Therefore, the present invention also relates to the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, or a composition containing same, as an inhibitor of vasodilation and / or increased vascular permeability.

[0071] The present invention relates to the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, or a composition containing same, for preventing and / or treating cosmetic disorders associated with excessive bradykinin synthesis and / or release.

[0072] As used herein, the term "prevent" or "prevention" refers to any action aimed at preventing the occurrence of an individual's discomfort or concern. As such, the term includes slowing, stopping, or limiting symptoms, i.e., paresthesia, but is limited to cosmetic aspects.

[0073] As used herein, the term "treat" or "treatment" refers to any action aimed at improving the comfort or well-being of an individual. As such, the term includes alleviating, mitigating, or suppressing symptoms, i.e., paresthesia, but is limited to cosmetic aspects.

[0074] The term "cosmetic disorder" refers to symptoms of discomfort, paresthesia, such as mildly unpleasant sensations felt in a certain zone of the skin, such as tightness, tingling, itching, heat, etc. It also refers to visual manifestations, such as redness, dilated blood vessels and / or telangiectasias of the skin.

[0075] The term "excessive bradykinin synthesis and / or release" refers to an increase in the synthesis of bradykinin and / or release of bradykinin in the skin of a subject relative to the average level of synthesis and / or release observed in that subject. The term "excess" as used herein means an increase of at least 20%, at least 50%, or at least 100%.

[0076] Preferably, the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, or a composition containing same according to the present invention is for preventing and / or reducing redness, vasodilation and / or telangiectasia of the skin.

[0077] Here, the term "redness" or "red spots" refers to the pink to red, or even dark red, coloration of all or part of the skin, scalp, mucous membranes, or semi-mucous membranes of the body. This appearance, also called erythema, may be a manifestation of a healthy complexion (rosy cheeks), however, although benign, it is often considered undesirable and unsightly.

[0078] This redness can be caused by a wide variety of factors, for example (i) external stimuli such as those caused by consumption of food or hot or alcoholic beverages, by sudden temperature changes, by heat or cold, by low relative humidity, by exposure of the skin to strong winds or drafts (fans, air conditioners), and by the application of certain surfactants, or (ii) redness associated with skin disorders, for example, rosacea, erythroderma, atopic dermatitis, seborrheic dermatitis, and (iii) redness following allergic skin reactions.

[0079] The term "external stimulus" means a stimulus which is not capable of causing trauma to the skin by itself, preferably selected from exposure of the skin to heat, cold, low relative humidity, strong winds or drafts.

[0080] As used herein, the term "cutaneous vasodilation" refers to benign vasodilation in all or part of the skin, scalp, mucous membranes, or semi-mucous membranes of the body, which is often considered undesirable and unsightly. This type of vasodilation is often temporary.

[0081] Preferably, the use of at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas, or a composition containing same according to the present invention is for preventing and / or reducing bradykinin-induced cutaneous vasodilation.

[0082] The term "telangiectasia" refers to the persistent, abnormal dilation of small blood vessels located near the surface of the skin and mucous membranes. These are typically tree-like or network-like, red to purple in color with fine lines and convolutions. They are more frequently found on the face or legs.

[0083] The present invention also relates to the use of at least one bacterium of the genus Sphingomonas according to the present invention, or an extract of a bacterium of the genus Sphingomonas, or a composition containing same, for preventing and / or reducing skin discomfort characterized by tightness, burning and / or itching.

[0084] method The present invention relates to a non-therapeutic cosmetic treatment method for skin redness, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas, or a composition comprising the same.

[0085] Preferably, application is made to a subject in need thereof with an effective amount of at least one bacterium of the genus Sphingomonas or at least one extract of a bacterium of the genus Sphingomonas.

[0086] Here, the term "effective amount" refers to the amount of extract of bacteria of the genus Sphingomonas that, as a whole, makes it possible to prevent and / or reduce redness of the skin, or the amount of bacteria of the genus Sphingomonas that, as a whole, makes it possible to prevent and / or reduce redness of the skin.

[0087] In the framework of the present invention, the term "skin" refers to any skin surface of the body, preferably the skin of the face.

[0088] The present invention also relates to a non-therapeutic cosmetic treatment method for sensitive skin, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas, or a composition comprising same.

[0089] Here, the term "sensitive skin" refers to intolerant skin that reacts to various factors, such as the application of cold or heat, through a sensation of heat, tightness and / or stinging.

[0090] In certain embodiments, cosmetic treatment methods for sensitive skin according to the present invention aim to prevent and / or reduce sensations of burning, tightness and / or stinging on the skin.

[0091] Preferably, application is made to a subject in need thereof with an effective amount of at least one bacterium of the genus Sphingomonas or at least one extract of a bacterium of the genus Sphingomonas.

[0092] Here, the term "effective amount" refers to the amount of extract of bacteria of the genus Sphingomonas that makes it possible to treat sensitive skin as a whole, or the amount of bacteria of the genus Sphingomonas that makes it possible to treat sensitive skin as a whole.

[0093] The bacterium applied in the method according to the present invention, or the bacterium of the extract applied, is a bacterium of the genus Sphingomonas. In an embodiment, the bacterium is selected from the group consisting of Sphingomonas abasii, Sphingomonas adhaesiba, Sphingomonas aerolata, Sphingomonas aquatilis, Sphingomonas asaccharolytica, Sphingomonas aurantiaca, Sphingomonas azotiphigens, Sphingomonas docdonensis, Sphingomonas echinoides, Sphingomonas faenii, Sphingomonas phoenica, Sphingomonas haloaromaticamanse, Sphingomonas jaspsi, Sphingomonas coriensis, Sphingomonas mali, Sphingomonas melonis, Sphingomonas natatoria ... The bacterium is a species selected from Sphingomonas oligophenolica, Sphingomonas pannii, Sphingomonas parapaucimobilis, Sphingomonas paucimobilis, Sphingomonas phyllosphaerae, Sphingomonas pityutosa, Sphingomonas prunii, Sphingomonas roseiflava, Sphingomonas sanguinis, Sphingomonas soli, Sphingomonas species, Sphingomonas suberifaciens, Sphingomonas tuleperi, Sphingomonas wittichii, Sphingomonas xenophagum, Sphingomonas yabuuchiae, Sphingomonas yunnanensis, and Sphingomonas yanoikue. In a specific embodiment, the bacterium is Sphingomonas xenophagum. In a preferred embodiment, the bacterium is Sphingomonas xenophagum, registered under the number CNCM I-5455 by L'Oreal (101 Avenue Gustave Eiffel, 37390 Notre Dame d'Oe) on November 21, 2019, in accordance with the Budapest Treaty, by the Collection Nationale de Culture de Microorganismes (CNCM, Paris, France).

[0094] Preferably, the method according to the invention comprises the step of topically applying at least one bacterium of the genus Sphingomonas or at least one extract of Sphingomonas according to the invention, or preferably a cosmetic composition comprising same. Preferably, the bacterium, extract or composition is applied to the face, legs or body, more preferably to the face.

[0095] As used herein, the term "subject" means a human.

[0096] According to the present invention, the method is a non-therapeutic method.

[0097] The methods of the invention may involve a single administration, hi another embodiment, administration is repeated, for example, two to three times per day, for one or more days, generally for an extended period of at least four weeks or from four to fifteen weeks, or as long as necessary, with optional interruptions if necessary.

[0098] In the following specification and examples, unless otherwise specified, percentages are percentages by weight, and ranges of values ​​stated as "between" include the specified upper and lower limits. The ingredients are mixed in an order and under conditions readily determined by one of ordinary skill in the art prior to packaging.

[0099] The present invention is further illustrated by the following examples. [Example]

[0100] Example 1 Preparation of the extract according to the invention Sphingomonas xenophagum strain CNCM-I 5455 was cultivated in a 3000 liter bioreactor in batch mode in complete culture medium, without adjusting the pH, maintaining the temperature at 26°C, and providing 30% dissolved oxygen.

[0101] The composition of the initial culture medium is listed in Table 1 below.

[0102] [Table 1]

[0103] Once the stable phase is reached, the cells are extracted and separated by centrifugation (10,000 g, continuous). The pellet, also called cell-containing biomass, is then collected and frozen at -20°C, then thawed to rupture the cells, thus obtaining the lysate. The lysate is then conditioned in a bag and finally stabilized by sterilization at 121°C for 30 minutes.

[0104] The lysate obtained at the end of the method described according to Example 1 contains 4.5% by weight of dry matter relative to the total weight of the lysate.

[0105] Example 2 In vitro study - dose / response curve of the effect of Sphingomonas extract on the activation of prekallikrein in normal plasma The effect of the extract of Example 1 on the substrate is monitored by spectrophotometric (λ=405 nm) measurement of the cleavage of the chromogenic substrate.

[0106] Enzyme activity was assessed by monitoring the kinetic reaction and calculating the maximum reaction velocity. Results represent the mean ± standard deviation of at least two replicates performed in two independent experiments. Statistical testing was performed using the Mann-Whitney test (α < 0.05).

[0107] The extract has a constant but specific absorption at a wavelength of 405 nm, so for all of the experiments it was necessary to subtract this specific absorption from the measured absorption.

[0108] Normal plasma containing the extract to be tested at concentrations of 0.02, 0.1, 0.2, 0.3, 0.4 and 0.5% is incubated at 0°C for 10 minutes, followed by complete activation of prekallikrein with dextran sulfate, and the activation of prekallikrein is assessed.

[0109] FIG. 1 shows the effect of an extract of Sphingomonas on the activation of prekallikrein in plasma.

[0110] At concentrations of 0.02, 0.1, 0.2, and 0.3%, the extract did not show any significant inhibitory effect (p>0.05). The inhibitory effect could be observed starting at a concentration of 0.4%. The inhibition of the kallikrein-kinin system was 46±8% and 90±8% at final concentrations of 0.4 and 0.5% (p<0.001; Figure 1). Thus, we confirmed the ability of the extract to inhibit the activation of the kallikrein-kinin system.

[0111] This can also be observed in Figure 2, which shows the percentage activity of plasma prekallikrein as a function of the extract concentration used.

[0112] In conclusion, the data obtained with the extract of Sphingomonas on the kallikrein-kinin system confirm the inhibitory effect on the activation of prekallikrein in normal plasma under the conditions experienced (activation of plasma after 10 minutes of incubation at 0° C.) In these conditions, the inhibitory effect is significant, starting from a concentration of 0.4% of the extract of Example 1.

[0113] Example 3 In vivo study - Evaluation of the sedative effect of Sphingomonas extract The test is carried out on 10 people divided into two groups. The test is carried out by administering 3.16 x 10 -3 %, followed by topical application of the composition containing the Sphingomonas extract of Example 1. The second group is a control group, which receives treatment with capsaicin but not with the composition containing the Sphingomonas extract. Skin irritated by capsaicin is used herein as a model of sensitive skin.

[0114] Compositions containing extracts of Sphingomonas used for the compositions:

[0115] [Table 2]

[0116] The redness of the skin in the test zone is rated by the clinician or the subject himself / herself on a scale of 0 to 4. In this way, the level of redness is: - After application of capsaicin and before application of the composition (T0 B ), - Immediately after application of the composition (T0 A ), then - 5, 10, 15, 20, 25 and 30 minutes after application of capsaicin It is rated as.

[0117] The changes in clinical scores are shown in Figure 3. The changes in scores given by the subjects themselves (hence self-assessment) are shown in Figure 4. In both graphs, it can be observed that the group receiving the composition containing the extract of Sphingomonas had lower scores than the control group. In these conditions, the composition containing the extract of Sphingomonas was able to reduce redness.

[0118] [Table 3]

Claims

1. 1. A composition for use as an inhibitor of bradykinin, comprising at least one bacterium of the genus Sphingomonas, or an extract of a bacterium of the genus Sphingomonas.

2. 10. The composition according to claim 1 for preventing and / or treating cosmetic disorders associated with excessive bradykinin synthesis and / or release.

3. A composition for preventing and / or reducing redness, vasodilation and / or telangiectasia of the skin, comprising at least one bacterium of the genus Sphingomonas or an extract of a bacterium of the genus Sphingomonas.

4. A composition for preventing and / or reducing skin discomfort characterized by tightness, stinging, burning and / or itching, the composition comprising at least one bacterium of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas.

5. 5. The composition of claim 1, wherein the bacterium is of the species Sphingomonas xenophaga.

6. 6. The composition according to claim 5, wherein the Sphingomonas xenophagum strain is the strain registered under accession number CNCM I-5455.

7. 7. The composition of claim 1, wherein the bacterial extract is a lysate.

8. A non-therapeutic cosmetic treatment method for skin redness, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or at least one extract of bacteria of the genus Sphingomonas, or a composition comprising at least one bacterium of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas.

9. A non-therapeutic cosmetic treatment method for sensitive skin, comprising the step of topically applying at least one bacterium of the genus Sphingomonas or at least one extract of bacteria of the genus Sphingomonas, or a composition comprising at least one bacterium of the genus Sphingomonas or an extract of bacteria of the genus Sphingomonas.

10. 10. A non-therapeutic cosmetic treatment method according to any one of claims 8 to 9, wherein the bacterium is of the species Sphingomonas xenophaga.

11. 11. A non-therapeutic cosmetic treatment method according to claim 10, wherein the strain of Sphingomonas xenophagum is the strain registered under accession number CNCM I-5455.

12. 12. A non-therapeutic cosmetic treatment method according to any one of claims 8 to 11, wherein the bacterial extract is a lysate.

Images